Diagnóstico y Terapias Locales



Similar documents
A Practical Guide to Advances in Staging and Treatment of NSCLC

CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV

Lung Cancer Treatment Guidelines

Alternatives to Surgical Resection for Early Stage Lung Cancer

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

The New International Staging System Lung Cancer

Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012

Stage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival

Radiation Therapy in the Treatment of

Moving forward, where are we with Clinical Trials?

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Kidney Cancer OVERVIEW

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

7. Prostate cancer in PSA relapse

Targeted Therapy What the Surgeon Needs to Know

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

The Need for Accurate Lung Cancer Staging

Chapter 2 Staging of Breast Cancer

Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA LUNG CANCER. IV. THERAPY. I. NON SMALL CELL LUNG CANCER Prof.

Lung cancer forms in tissues of the lung, usually in the cells lining air passages.

How To Know When To Stage Lung Cancer

SMALL CELL LUNG CANCER

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Probe: Could you tell me about when?

Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

Radioterapia panencefalica. Umberto Ricardi

Prognostic stratification of patients with T3N1M0 non-small cell lung cancer: which phase should it be?

Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians

Lung Cancer and Mesothelioma

An Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma

Thoracic surgery in Norway 2014 Norwegian Association for Cardiothoracic Surgery

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project

ROLE OF RADIATION THERAPY FOR RESECTABLE LUNG CANCER

Implementation Date: April 2015 Clinical Operations

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Management of low grade glioma s: update on recent trials

PET/CT in Lung Cancer

A Decade of Advances in Treatment of Early- Stage Lung Cancer

Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Evidence tabel Lokaal palliatieve behandelingen

Radiotherapy in locally advanced & metastatic NSC lung cancer

B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC

Lung Cancer Treatment

Image SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.

NCCN Non-Small Cell Lung Cancer V Update Meeting 07/09/10

Surgical Outcomes in Resected Non-small Cell Lung Cancer 1 cm in Diameter

An Update on Lung Cancer Diagnosis

How To Treat Lung Cancer At Cleveland Clinic

TITLE: Minimal Access Lobectomy for Lung Cancer Patients: A Review of the Clinical and Cost-Effectiveness

How To Compare The Effects Of A Hysterectomy And A Hysterectomy

The National Clinical Lung Cancer Audit (LUCADA)

RESEARCH EDUCATE ADVOCATE. Just Diagnosed with Melanoma Now What?

New Trends & Current Research in the Treatment of Lung Cancer, Pt. II

How To Treat A Uterine Sarcoma

The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer

General Information About Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines

SAKK Lung Cancer Group. Current activities and future projects

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.

Clinical Indications and Results Following Chest Wall Resection

Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS

Non-Small Cell Lung Cancer

TRATTAMENTO COMBINATO RADIO- CHEMIOTERAPICO NEL III STADIO NSCLC

Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board

a commitment in their practice to the roles and responsibilities of clinical oncologists X

Individual Prediction

Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.

Lung Cancer: Diagnosis, Staging and Treatment

Lungenkrebs. Lungenkrebs Häufigkeit

Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin

Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

Does my patient need more therapy after prostate cancer surgery?

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Lung Cancer: An Overview

Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

The Role of Laparoscopy in Endometrial Cancer

Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Radiocirugía y radioterapia estereotáxica corporal

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

Effective Health Care Program

Transcription:

Diagnóstico y Terapias Locales Dra Marga Majem Hospital de la Santa Creu i Sant Pau

AGENDA Revised (8th) Edition of TNM Staging System for Lung Cancer Surgical Approaches in Localized Lung Cancer Radiation for Localized Lung Cancer

AGENDA Revised (8th) Edition of TNM Staging System for Lung Cancer Surgical Approaches in Localized Lung Cancer Radiation for Localized Lung Cancer

Database for the 8th edition (Timelines: 2008-2017) Region Number % Europe 46,560 49 Asia 41,705 44 North America 4,660 5 Australia 1,593 1.7 South America 190 0.3 TOTAL 94,708 100 Rami-Porta R et al. J Thorac Oncol 2014; 9: 1618-1624 Presentation Number: 2042. Revised (8th) edition of TNM staging system for lung cancer Ramón Rami-Porta

T recommendations Descriptor 7th edition Proposal for 8th edition </= 1 cm T1a T1a > 1-2 cm T1a T1b > 2-3 cm T1b T1c > 3-4 cm T2a T2a > 4-5 cm T2a T2b > 5-7 cm T2b T3 > 7 cm T3 T4 Bronchus < 2 cm T3 T2 Complete atelectasis/pneumonitis T3 T2 Diaphragm invasion T3 T4 Mediastinal pleura T3 - Size: every cm counts (T1a-c) T2 & T3 endobronchial: same prognosis T2 & T3 atelectasis: same prognosis T3 diaphragm has a T4 prognosis T3 mediastinalpleura, rarely used Presentation Number: 2042. Revised (8th) edition of TNM staging system for lung cancer Ramón Rami-Porta

N recommendations To keep the present descriptors as they are To propose new descriptors for prospective testing: pn1a: single pn1 nodal station pn1b: multiple pn1 nodal stations pn2a1: single pn2 nodal station without pn1 (skip pn2) pn2a2: single pn2 nodal station with pn1 pn2b: multiple pn2 nodal stations N3: no changes M recommendations M1a: as it is M1b: single metastasis in a single organ M1c: multiple metastases in a single organ or in several organs Presentation Number: 2042. Revised (8th) edition of TNM staging system for lung cancer Ramón Rami-Porta Asamura H et al. JTO 2015; in press. Eberhardt W et al. JTO 2015; in press.

STAGING proposals N0 N1 N2 N3 M1a any N M1b any N M1c any N T1a IA1 IIB IIIA IIIB IVA IVA IVB T1b IA2 IIB IIIA IIIB IVA IVA IVB T1c IA3 IIB IIIA IIIB IVA IVA IVB T2a IB IIB IIIA IIIB IVA IVA IVB T2b IIA IIB IIIA IIIB IVA IVA IVB T3 IIB IIIA IIIB IIIC IVA IVA IVB T4 IIIA IIIA IIIB IIIC IVA IVA IVB Presentation Number: 2042. Revised (8th) edition of TNM staging system for lung cancer Ramón Rami-Porta

AGENDA Revised (8th) Edition of TNM Staging System for Lung Cancer Surgical Approaches in Localized Lung Cancer Radiation for Localized Lung Cancer

PRINCIPLES OF SURGICAL THERAPY Resection is the preferred local treatment RESECTION Anatomic pulmonary resectionis preferred for the majority of patients Sublobar resection: segmentectomy and wedge resection with: Margins > 2 cm or > the nodule size Appropriate N1 &N2 sampling Sublobar / wedge resection is appropriatein: Poor pulmonary reserve or major comorbidity that contraindicates lobectomy. Peripheral nodule < 2 cm with at least one of the following: Pure AIS histology. > 50% GGO in CT. Long doubling time (> 400 days) in radiologic surveillance.

PRINCIPLES OF RADIATION THERAPY Early-stage NSCLC (Stage I) SBRT is recommended for inoperable patients or those who refuse surgery. SBRT is appropriate for high surgical risk patients (do not tolerate lobectomy). SBRT comparable disease control rate and OS to lobectomy in operable disease. TheLancet, May 14, 2015: similar efficacy, lesstoxicity withsbrt

Surgical Approaches in Localized Lung Cancer ORAL35.02 -Wedge Resection vs Segmentectomy for Patients with T1A N0 Non-Small Cell Lung Cancer ORAL35.03 -Salvage Surgery for Local Failures after Stereotactic Ablative Radiotherapy for Lung Malignancies ORAL35.05 -The Role of Surgical Mediastinal Resection in CT Screen-Detected Lung Cancer Patients ORAL35.07 -The Feasibility and Safety of Complete VATS for NSCLC Under Non-Intubated Intravenous Anesthesia in Comparison with Intubated Anesthesia

ORAL 35.02 What is better?

Wedge resection might have lower perioperative mortality than lobectomy or segmentectomy. Retrospective database analysis Objective: To assess outcomes of patients who underwent wedge resection or segmentectomyfor stage T1aN0 NSCLC No differences in pts characteristics (1230 each arm)

CONCLUSIONS SegmentectomyforT1aN0M0 NSCLC patienthas betteros evenin < 1 cm tumors and forpatientswithno comorbidities Segmentectomyshouldbe thepreferred sublobar resectionfor ct1an0 NSCLC

ORAL 35.03

1 out of 4 lung tumors that are medically operable prefers SBRT. Carefully follow-up and early detection of local recurrence is critical. Limited information of salvage surgery after SBRT. MATERIAL AND METHODS 9 ptshad recurrence of early NSCLC 8 ptshad recurrence of lung mets, 4 ptstreated for lung mets underwent 2 separate resections for local recurrence

16/21 hadno furtherprogression OS aftersurgery: Median: 38 m 1 year: 100% 2 years: 80% CONCLUSIONS: Salvagesurgery for isolatedlocal recurrenceafterlung SBRT is feasiblewithoutmajorcomplications

ORAL35.05

Therapeutic value of MLNR continues to be a source of debate ACOSOG Z0030 trial: OS similar in early cancer with regard to complete LN resection vs LN sampling. Hypothesis: is MLNR necessary in small tumors detected by screening? I-ELCAP DATABASE RESECTED NSCLC More lobectomy and central tumors in the MLNR group

CONCLUSIONS For patients with small screen-diagnosed NSCLC it seems reasonable not to perform lymph node sampling, particularly in subsolidnodules. Future prospective studies are needed

ORAL 35.07

INTRODUCTION VATS usually performed under general anesthesiawith single-lung ventilation (GATI) Retrospective analysis of patients who received VATS radical resection of lung cancer under IV anesthesiawith spontaneous brathing (IASB) over 3 years

RESULTS Significantly lower postop stay in the intervention group. CONCLUSION: VATS under non-intubated anesthesia is safe and feasible and might have advantages in terms of post-op rehabilitation

AGENDA Revised (8th) Edition of TNM Staging System for Lung Cancer Surgical Approaches in Localized Lung Cancer Radiation for Localized Lung Cancer

Radiation for Localized Lung Cancer MINI18.01 -Stereotactic Body Radiation v. Observation for Early-Stage NSCLC in Elderly Patients ORAL19.01 -The SPACE Study: A Randomized Phase II Trial Comparing SBRT and 3DCRT in Stage I NSCLC Patients; Final Analysis including HRQL ORAL19.03 -NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiotherapy (SBRT) for Central Tumors -Adverse Events

MINI 18.01 Do we have to treat inoperable, elderly patients?

No random studies of observation vs SBRT in elderly, medically inoperable patients. Retrospective study. National Cancer Data Base NSCLC treated with SBRT or no treatment, > 70 years, T1-3N0M0, 2003-2006. Primary endpoint: OS SBRT: 258 pts No treatment: 2.889 pts Med age: 79 y All patients better survival with SBRT

CONCLUSION: SBRT reducesa36%therelativerisk of deathin elderlypatientsvsno treatment.

ORAL 19.01

Jan 2007-Jul 2011 N: 102 ( 49 SBRT, 53 DCRT) Follow up 37 months

CONCLUSIONS: SBRT has numerically less toxicity, better QoL, improved DCR.

ORAL19.03

INTRODUCTION SBRT is used for inoperablepatients with peripheral tumors. High toxicity observed for central tumors. Phase I/II trial Primary objective: To determine MTD of SBRT for centrally-located NSCLC and the tumor control rate at the MTD. METHODS: N: 120 pts HerearereportedAEsobservedin thetrial DLT andmtd submittedto ASTRO 2015

4 G5 toxicity: hemoptysisoccurringat 13 m post SBRT (range 5.5-14m) AlthoughSBRT waswelltolerated, 4/100 ptshadfatal hemoptysisattributableto SBRT. Verypreliminarydata

TAKE HOME MESSAGES Revised (8th) Editionof TNM More relevance to tumor size & reclassification of some T descriptors Acknowledgement of relevance of quantification of nodal disease Three metastatic groups More stages for better prognostic stratification Operable patients: For patients with small screen-diagnosed NSCLC it is reasonable not to perform lymph node sampling, particularly in subsolidnodules. VATS under non-intubated anesthesia is safe and feasible and might have advantages in terms of post-op rehabilitation

TAKE HOME MESSAGES Operable patients: Patientsnotsuitable for lobectomy: Segmentectomy should be thepreferred sublobar resectionforct1an0 NSCLC. Salvagesurgeryforlocal recurrenceafterlungsbrt is feasiblewithoutmajorcomplications. Inoperable patients: SBRT in elderly, medicallyinoperable patientsseemsbetter thanobservationin ct1-3n0m0 tumors. In NSCLC T1-2 < 6cm SBRT presents numericallyless toxicity, betterqol, improved DCR (Phase II). Notreadyfor SBRT in central NSCLC tumors.

Dra Marga Majem Hospital de la Santa Creu i Sant Pau